XML 54 R37.htm IDEA: XBRL DOCUMENT
v3.20.2

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended |
--- | --- | --- | ---
Sep. 30, 2020 | Sep. 30, 2019 | Sep. 30, 2020 | Sep. 30, 2019 | Dec. 31, 2019
Property, Plant and Equipment [Line Items] |  |  |  |  |
Impairment of intangible assets |  |  | $ 584,509 | $ 78,864 |
Amortization of intellectual property license fee | $ 762,389 | $ 15,998 | 2,262,002 | 15,998 |
Inventory valuation reserves | 5,744,464 |  | $ 5,744,464 |  | $ 0
Council License Agreement [Member] |  |  |  |  |
Property, Plant and Equipment [Line Items] |  |  |  |  |
Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent |  |  | 50.00% |  |
Annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent |  |  | 20.00% |  |
Maximum costs and expenses for post approval |  |  | $ 20,000,000 |  |
Council License Agreement Step 1 |  |  |  |  |
Property, Plant and Equipment [Line Items] |  |  |  |  |
Royalty (percent) |  |  | 5.00% |  |
Council License Agreement Step 2 |  |  |  |  |
Property, Plant and Equipment [Line Items] |  |  |  |  |
Royalty (percent) |  |  | 10.00% |  |
Council License Agreement Step 3 |  |  |  |  |
Property, Plant and Equipment [Line Items] |  |  |  |  |
Royalty (percent) |  |  | 15.00% |  |
Vitamins and IMVEXXY [Member] |  |  |  |  |
Property, Plant and Equipment [Line Items] |  |  |  |  |
Shelf life of prescription products following product expiration |  |  | 24 months |  |
BIJUVA and ANNOVERA [Member] |  |  |  |  |
Property, Plant and Equipment [Line Items] |  |  |  |  |
Shelf life of prescription products following product expiration |  |  | 18 months |  |
BIJUVA and ANNOVERA [Member] | Knight License Agreement [Member] |  |  |  |  |
Property, Plant and Equipment [Line Items] |  |  |  |  |
Milestone payment received upon regulatory approval | $ 2,000,000 |  |  |  |
ANNOVERA [Member] | Council License Agreement [Member] |  |  |  |  |
Property, Plant and Equipment [Line Items] |  |  |  |  |
Milestone payment upon FDA Approval |  |  | $ 20,000,000 |  |
Milestone payments (payment after release of first commercial batch) |  |  | 20,000,000 |  |
License rights acquired |  |  | 20,000,000 |  |
Milestone payments upon specified levels of cumulative net sales |  |  | 40,000,000 |  |
Specified level one of cumulative net sales for milestone payments |  |  | 200,000,000 |  |
Specified level two of cumulative net sales for milestone payments |  |  | 400,000,000 |  |
Specified level three of cumulative net sales for milestone payments |  |  | $ 1,000,000,000 |  |
Minimum [Member] |  |  |  |  |
Property, Plant and Equipment [Line Items] |  |  |  |  |
Return period of unsalable prescription products |  |  | 6 months |  |
Minimum [Member] | Council License Agreement Step 2 |  |  |  |  |
Property, Plant and Equipment [Line Items] |  |  |  |  |
Net sales amount per step-based royalty |  |  | $ 50,000,000 |  |
Minimum [Member] | Council License Agreement Step 3 |  |  |  |  |
Property, Plant and Equipment [Line Items] |  |  |  |  |
Net sales amount per step-based royalty |  |  | $ 150,000,000 |  |
Maximum [Member] |  |  |  |  |
Property, Plant and Equipment [Line Items] |  |  |  |  |
Return period of unsalable prescription products |  |  | 12 months |  |
Maximum [Member] | Council License Agreement Step 1 |  |  |  |  |
Property, Plant and Equipment [Line Items] |  |  |  |  |
Net sales amount per step-based royalty |  |  | $ 50,000,000 |  |
Maximum [Member] | Council License Agreement Step 2 |  |  |  |  |
Property, Plant and Equipment [Line Items] |  |  |  |  |
Net sales amount per step-based royalty |  |  | $ 150,000,000 |  |
Performance Shares [Member] |  |  |  |  |
Property, Plant and Equipment [Line Items] |  |  |  |  |
Common stock, shares, issued (in dollars per share) | $ 0.001 |  | $ 0.001 |  |
Restricted Stock [Member] |  |  |  |  |
Property, Plant and Equipment [Line Items] |  |  |  |  |
Common stock, shares, issued (in dollars per share) | $ 0.001 |  | $ 0.001 |  |
Trademarks and Trade Names [Member] |  |  |  |  |
Property, Plant and Equipment [Line Items] |  |  |  |  |
Impairment of intangible assets |  |  | $ 584,509 | 78,864 |
Fair Value, Recurring [Member] |  |  |  |  |
Property, Plant and Equipment [Line Items] |  |  |  |  |
Assets or liabilities valued at fair value | $ 0 | $ 0 | $ 0 | $ 0 |

X
- Definition The amount represents amortization of intellectual property license fee. + References No definition available. + Details
Name: | txmd_AmortizationOfIntellectualPropertyLicenseFee
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The percentage of annual royalty rate reduction of initial rate after six-month period from commercial sale of a generic equivalent. + References No definition available. + Details
Name: | txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent
Namespace Prefix: | txmd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S. + References No definition available. + Details
Name: | txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent
Namespace Prefix: | txmd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement. + References No definition available. + Details
Name: | txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of milestone payment received upon regulatory approval. + References No definition available. + Details
Name: | txmd_MilestonePaymentReceivedUponRegulatoryApproval
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of milestone payments upon FDA approval. + References No definition available. + Details
Name: | txmd_MilestonePaymentUponFDAApproval
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of milestone payments payable after release of first commercial batch. + References No definition available. + Details
Name: | txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payments due upon specified levels of cumulative net sales for under agreement. + References No definition available. + Details
Name: | txmd_MilestonePaymentsUponSpecifiedLevelsOfCumulativeNetSales
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The net sales amount as defined in license agreement for step-based royalty payments. + References No definition available. + Details
Name: | txmd_NetSalesAmountPerStepbasedRoyalty
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Period the company accepts returns of unsalable prescription products from customers following product expiration. + References No definition available. + Details
Name: | txmd_ReturnPeriodOfUnsalablePrescriptionProducts
Namespace Prefix: | txmd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percent of the net sales to be paid as royalty per license agreement. + References No definition available. + Details
Name: | txmd_RoyaltyPercent
Namespace Prefix: | txmd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period shelf life of prescription products from date of manufacture. + References No definition available. + Details
Name: | txmd_ShelfLifeOfPrescriptionProducts
Namespace Prefix: | txmd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount represents specified level one of cumulative net sales for milestone payments. + References No definition available. + Details
Name: | txmd_SpecifiedLevelOneOfCumulativeNetSalesForMilestonePayments
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount represents specified level three of cumulative net sales for milestone payments. + References No definition available. + Details
Name: | txmd_SpecifiedLevelThreeOfCumulativeNetSalesForMilestonePayments
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount represents specified level two of cumulative net sales for milestone payments. + References No definition available. + Details
Name: | txmd_SpecifiedLevelTwoOfCumulativeNetSalesForMilestonePayments
Namespace Prefix: | txmd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Fair value of asset after deduction of liability. + References No definition available. + Details
Name: | us-gaap_FairValueNetAssetLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_FinitelivedIntangibleAssetsAcquired1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of valuation reserve for inventory. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.BB) -URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SX 210.12-09) -URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.6(a)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_InventoryValuationReserves
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_PropertyPlantAndEquipmentLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=txmd_VitaminsAndImvexxyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=txmd_BijuvaAndAnnoveraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=txmd_KnightLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=txmd_AnnoveraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |